Next Article in Journal
Pharmacological Potential of Sea Cucumbers
Next Article in Special Issue
NAD(P)H Oxidase Activity in the Small Intestine Is Predominantly Found in Enterocytes, Not Professional Phagocytes
Previous Article in Journal
Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
Previous Article in Special Issue
Extracellular Vesicles as Conveyors of Membrane-Derived Bioactive Lipids in Immune System
Open AccessReview

Mechanisms of Intrinsic Tumor Resistance to Immunotherapy

1
Department of Surgery, University of Minnesota Medical School, 11-212 Moos Tower, Mayo Mail Code 195, 420 Delaware Street SE, Minneapolis, MN 55455, USA
2
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1340; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms19051340
Received: 6 April 2018 / Revised: 27 April 2018 / Accepted: 28 April 2018 / Published: 2 May 2018
(This article belongs to the Special Issue Signaling Pathway of Immune Cells and Immune Disorder)
An increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope. View Full-Text
Keywords: cancer immunotherapy; resistance; oncogenes; signaling pathways cancer immunotherapy; resistance; oncogenes; signaling pathways
Show Figures

Graphical abstract

MDPI and ACS Style

Rieth, J.; Subramanian, S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int. J. Mol. Sci. 2018, 19, 1340. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms19051340

AMA Style

Rieth J, Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. International Journal of Molecular Sciences. 2018; 19(5):1340. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms19051340

Chicago/Turabian Style

Rieth, John; Subramanian, Subbaya. 2018. "Mechanisms of Intrinsic Tumor Resistance to Immunotherapy" Int. J. Mol. Sci. 19, no. 5: 1340. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms19051340

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop